Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases

Dorann Bartebin, Jerome Hadjadj, Laure Croisille, Emilie Letoriellec, Corinne Haioun, Delphine Gobert, Antoine Dossier, Olivier Fain, Matthieu Mahevas, Bertrand Godeau, Karim Sacré, Marc Michel, Etienne Crickx

Blood (2025) 146 (Supplement 1): 2984.

https://doi.org/10.1182/blood-2025-2984

Published: 2025

Journal Articles

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Francesco Zaja, Adam Cuker, Hanny Al-Samkari, Marc Michel, Yogesh Chattar, Matthew Foster, Meritxell Vendranas, Nicola Cooper

Blood (2025) 146 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2025-6586

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Blood (2025) 146 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2025-1100

Published: 2025

Journal Articles

The prolong trial: A two Phase randomized placebo-controlled trial to optimize rituximab response with dexamethasone and maintenance therapy with low dose rituximab in immune thrombocytopenia (ITP) patients

Waleed Ghanima, Doaa El Demerdash, Henrik Frederiksen, James Bussel, Galina Tsykunova, Marc Michel, Hoa Tran, Carina Nassar, Bernadette Darne, Eirik Tjønnfjord, Tor Henrik Tvedt, Fehmi M'Sadek, Mervat Mattar, Abderraheem Khelif, Pål Holme

Blood (2025) 146 (Supplement 1): 736.

https://doi.org/10.1182/blood-2025-736

Published: 2025

Journal Articles

HLH-JAK, the first OPEN-label, phase II study evaluating ANTI-JAK1 itacitinib, for NON severe HLH in adults.

Coralie Bloch, Marouane Boubaya, Estibaliz Lazarro, Louis Terriou, Marc Michel, Julien Carvelli, Olivier Hermine

Blood (2025) 146 (Supplement 1): 190.

https://doi.org/10.1182/blood-2025-190

Published: 2025

Journal Articles

Characteristics at diagnosis of autoimmune hemolytic anemias in adults: First results from a prospective, multicenter cohort of 413 patients included in the carmen-France registry

Yoann Zadro, Marc Michel, Matthieu Mahevas, Thibault Comont, Jean-Francois Viallard, Mikael Ebbo, Jehane Fadlallah, Stephane Cheze, Louis Terriou, Thomas Moulinet, Marc Ruivard, Clément Gourguechon, Aurélie Saunier, Antoine Dossier, Ailsa Robbins, Bernard Bonnotte, Bertrand Godeau, Sylvain Audia, Guillaume Moulis

Blood (2025) 146 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2025-4660

Published: 2025

Journal Articles

Estimation of post-transfusion HbA level is relevant after RBC exchange in sickle cell adult patients

Capucine Belcadi, Armand Mekontso Dessap, Stephane Moutereau, Gonzalo De Luna, Constance Guillaud, Fatima Bansiradj, Geoffroy Volle, Etienne Crickx, Anaïs BOURGUIGNON D'HERBIGNY, Marc Michel, France Pirenne, Pablo Bartolucci, Anoosha Habibi

Blood (2025) 146 (Supplement 1): 6503.

https://doi.org/10.1182/blood-2025-6503

Published: 2025

Journal Articles

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Monica Carpenedo, Catherine Broome, Blanca Sánchez González, Vickie McDonald, Yoshitaka Miyakawa, Kaichi Nishiwaki, Francesco Zaja, Hanny Al-Samkari, Filip Matthijssens, Damien Chimits, Jaume Ayguasanosa, Syed Raza, Giles Monnickendam, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2025) 146 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2025-6245

Published: 2025

Journal Articles

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Alexander Röth, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Kelley Dacus, Mounia Beloueche, Catherine Broome

Blood (2025) 146 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2025-6242

Published: 2025

Journal Articles

Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections

Blood (2025) 146 (Supplement 1): 4818.

https://doi.org/10.1182/blood-2025-4818

Published: 2025

Journal Articles

Real-world effectiveness and safety of fostamatinib in difficult-to-treat patients: Results of a three-year registry in France.

Blood (2025) 146 (Supplement 1): 4805.

https://doi.org/10.1182/blood-2025-4805

Published: 2025

Journal Articles

Rilzabrutinib, the first-in-class BTK inhibitor for ITP

Marc Michel

Blood (2025) 145 (24): 2810–2812.

https://doi.org/10.1182/blood.2025028584

Published: 2025

Journal Articles

Long-term follow-up of the STOPAGO study

Blood (2025) 145 (2): 244–247.

https://doi.org/10.1182/blood.2024025707

Published: 2025

Includes: Supplemental data

Journal Articles

Insights on the Lived Experience of Warm Autoimmune Hemolytic Anemia (wAIHA) from an Ongoing Patient Council

Merel Güttinger, Karen A Jones, Maartje Mangelaars, Sandya R. Panch, Marc Michel

Blood (2024) 144 (Supplement 1): 7693.

https://doi.org/10.1182/blood-2024-205079

Published: 2024

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Blood (2024) 144 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2024-204053

Published: 2024

Journal Articles

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Catherine M. Broome, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Jiangming Wu, Shruti Srivastava, Marek Wardęcki, Reena Patel, Ronnie Yoo, Alexander Röth

Blood (2024) 144 (Supplement 1): 7667.

https://doi.org/10.1182/blood-2024-206942

Published: 2024

Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker

Blood (2023) 142 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2023-180647

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

The prolong trial: A two Phase randomized placebo-controlled trial to optimize rituximab response with dexamethasone and maintenance therapy with low dose rituximab in immune thrombocytopenia (ITP) patients

HLH-JAK, the first OPEN-label, phase II study evaluating ANTI-JAK1 itacitinib, for NON severe HLH in adults.

Characteristics at diagnosis of autoimmune hemolytic anemias in adults: First results from a prospective, multicenter cohort of 413 patients included in the carmen-France registry

Estimation of post-transfusion HbA level is relevant after RBC exchange in sickle cell adult patients

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections

Real-world effectiveness and safety of fostamatinib in difficult-to-treat patients: Results of a three-year registry in France.

Rilzabrutinib, the first-in-class BTK inhibitor for ITP

Long-term follow-up of the STOPAGO study

Insights on the Lived Experience of Warm Autoimmune Hemolytic Anemia (wAIHA) from an Ongoing Patient Council

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only